137 related articles for article (PubMed ID: 11312916)
1. Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
Stilz HU; Guba W; Jablonka B; Just M; Klingler O; König W; Wehner V; Zoller G
J Med Chem; 2001 Apr; 44(8):1158-76. PubMed ID: 11312916
[TBL] [Abstract][Full Text] [Related]
2. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
3. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
[TBL] [Abstract][Full Text] [Related]
5. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
Andronati SA; Karaseva TL; Krysko AA
Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
[TBL] [Abstract][Full Text] [Related]
6. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
[TBL] [Abstract][Full Text] [Related]
7. SR 121787, a new orally active fibrinogen receptor antagonist.
Savi P; Badorc A; Lalé A; Bordes MF; Bornia J; Labouret C; Bernat A; de Cointet P; Hoffmann P; Maffrand JP; Herbert JM
Thromb Haemost; 1998 Sep; 80(3):469-76. PubMed ID: 9759629
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist.
Hayashi Y; Katada J; Sato Y; Igarashi K; Takiguchi Y; Harada T; Muramatsu M; Yasuda E; Uno I
Bioorg Med Chem; 1998 Mar; 6(3):355-64. PubMed ID: 9568289
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
[TBL] [Abstract][Full Text] [Related]
10. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
Weller T; Alig L; Beresini M; Blackburn B; Bunting S; Hadváry P; Müller MH; Knopp D; Levet-Trafit B; Lipari MT; Modi NB; Müller M; Refino CJ; Schmitt M; Schönholzer P; Weiss S; Steiner B
J Med Chem; 1996 Aug; 39(16):3139-47. PubMed ID: 8759635
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
12. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
[TBL] [Abstract][Full Text] [Related]
13. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
[TBL] [Abstract][Full Text] [Related]
14. Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.
Bovy PR; Tjoeng FS; Rico JG; Rogers TE; Lindmark RJ; Zablocki JA; Garland RB; McMackins DE; Dayringer H; Tóth MV
Bioorg Med Chem; 1994 Sep; 2(9):881-95. PubMed ID: 7712124
[TBL] [Abstract][Full Text] [Related]
15. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
[TBL] [Abstract][Full Text] [Related]
16. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.
Barre DE
Thromb Res; 2007; 119(5):601-7. PubMed ID: 16860375
[TBL] [Abstract][Full Text] [Related]
17. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
Rahman S; Lu X; Kakkar VV; Authi KS
Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
[TBL] [Abstract][Full Text] [Related]
18. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight, non-peptide fibrinogen receptor antagonists.
Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T
J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419.
Yamanaka T; Ohkubo M; Kuroda S; Nakamura H; Takahashi F; Aoki T; Mihara K; Seki J; Kato M
Bioorg Med Chem; 2005 Jul; 13(13):4343-52. PubMed ID: 15927840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
